News | 29 November 2023
Bayer commits to Veeva Vault CRM and Veeva OpenData globally
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Both the India and GCC entities will be operated by separate dedicated management teams
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Distributes Ayushman cards to several beneficiaries
Evinova will operate as a separate health-tech business within AstraZeneca
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Subscribe To Our Newsletter & Stay Updated
